Abstract
All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity.
Beteiligte Forschungseinheiten
Leibniz-HKI-Autor*innen
Identifier
doi: 10.1056/NEJMoa1300874
PMID: 23841729